Comparison of Effectiveness Using Different Dual Bronchodilator Agents in Chronic Obstructive Pulmonary Disease Treatment

The effectiveness and safety of fixed dual long-acting bronchodilators for chronic obstructive pulmonary disease (COPD) patients have been well established; however, there is a paucity clinical comparison in with COPD treatment. aim the current study was to compare three once-daily bronchodilator agents COPD. Patients diagnosed treated beta-agonist (LABA) + muscarinic antagonist (LAMA) fixed-dose combination therapy (UME/VIL (umeclidinium vilanterol inhalation powder), IND/GLY (indacaterol glycopyrronium), TIO/OLO (tiotropium olodaterol)) were enrolled this retrospective over period 12 months. Effectiveness assessments evaluated using assessment test (CAT) lung function parameters. Besides, times acute exacerbation also assessed. patients’ number 177 IND/GLY, 176 UME/VIL 183 TIO/OLO. Lung measurements FEV1 had significantly improved (98.7 mL) compared those (65.2 (64.4 (p < 0.001). CAT scores decreased (CAT down 5.6) than (3.8) (3.9) = 0.03). Acute reduced (4.9%) (10.2%) (11.9%) 0.01). Significant improvement function, symptoms demonstrated after months LABA/LAMA different treatment options. higher therapeutic effects or IND/GLY. Determining relevance will require well-designed randomized controlled trial.